Ticagrelor, even better than we thought

Original title: Reduction in First and Recurrent Cardiovascular Events with Ticagrelor Compared with Clopidogrel in the PLATO Study. Reference: Payal Kohli et al. CIRCULATION AHA.112.124248. In analyzing randomized and monitored study outcomes, we usually observe that after the occurrence of any primary outcome event patients are typically blocked for further analysis.  This practice limits the information on subsequent<a href="https://solaci.org/en/2013/01/08/ticagrelor-even-better-than-we-thought/" title="Read more" >...</a>

In patients with stroke history, Ticagrelor is superior to Clopidogrel

James SK, Storey RF, Khurmi N, et al. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes and a History of Stroke or Transient Ischemic Attack. Circulation 2012. A sub-analysis of the PLATO study demonstrated similar superiority and the safety of ticagrelor in all patients, regardless of any previous history of stroke. Ticagrelor versus clopidogrel:<a href="https://solaci.org/en/2012/09/01/in-patients-with-stroke-history-ticagrelor-is-superior-to-clopidogrel/" title="Read more" >...</a>

Ticagrelor vs. Clopidogrel in ST elevation MI: Pros and cons

Platelet Inhibition in the PLATO study: insights from the ECG substudy. En el Estudio PLATO quedó evidenciado que el Ticagrelor disminuyó la mortalidad a 12 meses en comparación con el Clopidogrel en el tratamiento de pacientes post-angioplastía por un síndrome coronario agudo o por un cuadro estable (4,5 vs. 5,9%; P<0.001). Estos resultados fueron del<a href="https://solaci.org/en/2011/01/01/ticagrelor-vs-clopidogrel-in-st-elevation-mi-pros-and-cons/" title="Read more" >...</a>

Prehospital Crushed vs. Integral Prasugrel in STEMI Patients with Large Myocardial Area at Risk

Timely percutaneous intervention of STEMI patients effectively reduces MI size and mortality, which currently makes it the first line of treatment. A fundamental aspect is activation and platelet aggregation, which is why, in addition to creating networks to optimize STEMI treatment, prehospital drug treatments have been implemented.  The COMPARECrush looked at whether early and powerful<a href="https://solaci.org/en/2024/07/08/prehospital-crushed-vs-integral-prasugrel-in-stemi-patients-with-large-myocardial-area-at-risk/" title="Read more" >...</a>

Intervención tricuspídea heterotópica: Resultados de TricValve a un año

High Gradients After Valve-in-Valve

One of the limitations of aortic bioprostheses is their durability. When these devices fail, percutaneous valve implantation is a valid strategy. However, it has been shown that there may be high gradients involved. This gradient increase has been associated with worse outcomes and higher mortality rates, as observed in the PARTNER 2 study at 12 months.<a href="https://solaci.org/en/2024/06/18/high-gradients-after-valve-in-valve/" title="Read more" >...</a>

ACC 2024 | ULTIMATE-DAPT Trial

The international guidelines recommend the use of dual antiplatelet therapy (DAPT) with aspirin plus a P2Y12 inhibitor during 12 months in patients receiving percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS), to prevent events such as MI and stent thrombosis.  This was a multicenter, placebo controlled, double blind study to determine whether ticagrelor alone,<a href="https://solaci.org/en/2024/04/10/acc-2024-ultimate-dapt-trial/" title="Read more" >...</a>

TCT 2023 | In Stent Restenosis: Sirolimus vs. Paclitaxel Coated Balloons

This was a prospective, multicenter, randomized study including 130 patients with instent restenosis treated with sirolimus coated balloons (DCB S) and 128 treated with paclitaxel coated balloons (DCB P).  Primary end point was late lumen loss (LLL) at 12 months.  There were no significant differences between the groups. Mean patient age was 63, 75% were<a href="https://solaci.org/en/2023/10/30/tct-2023-in-stent-restenosis-sirolimus-vs-paclitaxel-coated-balloons/" title="Read more" >...</a>

Dietas bajas en carbohidratos y progresión de la calcificación coronaria

Coronary Artery Calcium on Non–ECG-Gated Chest CTs: Mere Finding or Therapeutic Opportunity?

CAD related acute phenomena often present as a consequence of poor risk factor monitoring over time. Early detection of these patients, especially high risk patients, has significantly contributed to reducing morbimortality over time.  Coronary artery calcification (CAC) is considered a measure of atherosclerosis burden in and might be present in asymptomatic individuals. Most centers do<a href="https://solaci.org/en/2023/09/26/coronary-artery-calcium-on-non-ecg-gated-chest-cts-mere-finding-or-therapeutic-opportunity/" title="Read more" >...</a>

La cirugía parece superior a la angioplastia en pacientes jóvenes

ISCHEMIA Trial: Does Complete Anatomical or Functional Revascularization Modify Anything Compared with Medical Treatment?

Chronic coronary syndrome (CCS) has been considered another comorbidity in previous studies, and there has been no significant reduction in cardiovascular mortality or myocardial infarction (MI) rates with revascularization through percutaneous coronary intervention (PCI) or myocardial revascularization surgery (MRS) compared with optimal medical treatment (OMT). One possible reason for the lack of benefit has been<a href="https://solaci.org/en/2023/09/21/ischemia-trial-does-complete-anatomical-or-functional-revascularization-modify-anything-compared-with-medical-treatment/" title="Read more" >...</a>

ESC 2023 | STOPDAPT-3

Short Dual antiplatelet therapy (DAPT), one to three months, followed by P2Y12 inhibitor monotherapy has been shown to reduce bleeding events without increased cardiovascular events vs. standard DAPT, according to guidelines.  However, the rate of major bleeding within the first month after procedure remains significant when using these strategies.  The use of aspirin-free therapies (ASA)<a href="https://solaci.org/en/2023/08/29/esc-2023-stopdapt-3-2/" title="Read more" >...</a>